Candida species from oral cavity of HIV-infected children exhibit reduced virulence factors in the HAART era

Microb Pathog. 2017 Jan:102:74-81. doi: 10.1016/j.micpath.2016.11.020. Epub 2016 Nov 29.

Abstract

This study aimed to assess, in vitro, the biofilm viability and the phospholipase and protease production of Candida spp. from the saliva of HIV infected children and healthy controls, and to correlate the results with the use of medical data. A total of 79 isolates were analyzed: 48 Candida albicans isolates (33/15) and 20 Candida parapsilosis sensu lato complex isolates (12/8) (from HIV/control patients, respectively), and 8 Candida krusei, 1 Candida tropicalis, 1 Candida dubliniensis and 1 Candida guilliermondii from HIV patients. The XTT (2, 3-bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-Carboxanilide) reduction assay analyzed the biofilm viability. Phospholipase and protease assays were performed using the egg yolk and Bovine Serum Albumin agar plate methods, respectively. All isolates were able to form biofilm with cell viability. Quantitatively, Candida isolates from both groups presented a similar ability to form biofilm (p > 0.05). The biofilm viability activity was higher in C. albicans isolates than in non-albicans Candida isolates (p < 0.05) for both groups. Phospholipase activity was detected in 32 isolates (40.5%) and it was significantly higher in the HIV group (p = 0.006). Protease activity was detected in 66 isolates (84.8%) and most of them were relatively/very strong producers. No statistical association with medical data was found in the HIV group. Although Candida spp. isolates from HIV-positive children presented higher phospholipase production, in vitro they exhibited reduced virulence factors compared to isolates from healthy individuals. This finding may enlighten the role played by immunosuppression in the modulation of Candida virulence attributes.

Keywords: Biofilm formation; Candida; HIV-Infected children; Phospholipase; Protease; Virulence factors.

MeSH terms

  • Antiretroviral Therapy, Highly Active
  • Biofilms
  • Candida / classification*
  • Candida / pathogenicity*
  • Candidiasis, Oral / diagnosis
  • Candidiasis, Oral / immunology
  • Candidiasis, Oral / microbiology*
  • Child
  • Coinfection*
  • Comorbidity
  • Cross-Sectional Studies
  • Female
  • HIV Infections* / diagnosis
  • HIV Infections* / drug therapy
  • HIV Infections* / immunology
  • HIV Infections* / virology
  • Humans
  • Male
  • Phenotype
  • Viral Load
  • Virulence Factors

Substances

  • Virulence Factors